最新报道:Eli Lilly's obesity pill orforglipron demonstrated 11.2% weight loss in a major clinical trial, with side effects comparable to current injectable treatments, according to doctors at the European Association for the Study of Diabetes meeting. Full data from the trial is being presented and published in the New England Journal of Medicine.